Biote Corp. (BTMD) - Q1 2025 10-Q Summary
Business Context and Reporting Period
Company: Biote Corp.
Reporting Period: Quarter ended March 31, 2025
Business Model: Biote trains physicians and nurse practitioners in therapeutic wellness and hormone optimization using bioidentical hormone replacement pellet therapy. The company also sells Biote-branded dietary supplements and provides practice management software. The company operates as a single segment and is an emerging growth company.
Key Financial Metrics
| Metric (in thousands) | Q1 2025 | Q1 2024 |
|---|---|---|
| Total Revenue | $48,992 | $46,804 |
| Net Income (Loss) | $15,839 | $(5,726) |
| Net Income Attributable to Stockholders | $13,718 | $(4,161) |
| Diluted EPS | $0.37 | $(0.12) |
| Operating Cash Flow | $6,467 | $7,372 |
| Cash and Equivalents (End of Period) | $41,700 | $78,787 |
| Total Debt (Term Loan) | $107,812 | $109,375 |
| Adjusted EBITDA | $13,752 | $14,158 |
Material Changes vs. Prior Period
- Profitability Turnaround: The company reported a net income of $15.8 million in Q1 2025, a significant improvement from a net loss of $5.7 million in Q1 2024. This was primarily driven by a $10.7 million gain from the change in fair value of earnout liabilities, compared to a $12.1 million loss in the prior year.
- Revenue Growth: Total revenue increased 4.7% to $49.0 million. Growth was driven by a $1.9 million increase in dietary supplement revenue (due to a shift to e-commerce) and a $1.2 million increase in service revenue. This was partially offset by a $1.3 million decrease in pellet procedure revenue due to a slowdown in new clinic additions.
- Expense Increases: Selling, general, and administrative (SG&A) expenses rose 16.4% to $26.7 million, attributed to increased marketing, legal fees (including litigation settlements), and bad debt expenses.
- Interest Expense: Net interest expense increased to $2.9 million, largely due to $1.1 million in accreted interest related to share repurchase liabilities.
Guidance, Outlook, Risks, and Unusual Items
- CEO Transition: Bret Christensen was appointed CEO on February 1, 2025, succeeding Teresa S. Weber, who transitioned to a strategic advisor role.
- Restructuring Plan: In May 2025, the Board approved a restructuring plan involving the commercial team, estimating pre-tax charges of $0.6 million to $0.8 million to be incurred in Q2 2025.
- Legal Settlements: The company settled the "Right Value Litigation" for $5.0 million ($3.5 million paid in Q1 2025, $1.5 million remaining). Other ongoing litigation includes matters involving Cindy Latch (injunction reversed on appeal) and Dr. Gary S. Donovitz (appeals pending).
- Internal Controls: The company disclosed that disclosure controls and procedures were not effective as of March 31, 2025, due to a previously identified material weakness in the internal control environment (specifically regarding technical accounting personnel and IT general controls) that has not yet been remediated.
- Supply Chain: A key vendor, AnazaoHealth, notified the company of contract termination effective May 1, 2025. The company believes it can meet demand through its own manufacturing (Asteria Health) and other vendors.
Investor Verification Checklist
- Earnout Liability Volatility: Verify the sustainability of the $10.7 million gain from earnout liability revaluation, which was the primary driver of net income. This is a non-cash item sensitive to stock price fluctuations.
- Internal Control Remediation: Monitor the progress of remediation efforts for the material weakness in internal controls over financial reporting, which currently renders disclosure controls ineffective.
- Legal Exposure: Track the status of ongoing litigation (Donovitz, Latch) and the impact of the $1.5 million remaining liability from the Right Value settlement.
- Supply Chain Continuity: Assess the operational impact of the AnazaoHealth contract termination and the company's ability to scale its own manufacturing capabilities to fill the gap.
- Restructuring Costs: Confirm the actual costs and timeline of the Q2 2025 restructuring plan announced in May 2025.